Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1979 2
1980 1
1981 2
1982 5
1983 1
1984 3
1985 2
1986 4
1987 2
1988 6
1989 2
1990 2
1991 2
1992 2
1993 4
1994 4
1995 1
1996 2
1997 4
1998 1
1999 7
2000 5
2001 8
2002 6
2003 12
2004 21
2005 21
2006 27
2007 42
2008 30
2009 28
2010 30
2011 47
2012 48
2013 52
2014 57
2015 68
2016 73
2017 108
2018 92
2019 104
2020 108
2021 92
2022 81
2023 106
2024 35

Text availability

Article attribute

Article type

Publication date

Search Results

1,246 results

Results by year

Filters applied: . Clear all
Page 1
Xenotransplantation: Current Challenges and Emerging Solutions.
Arabi TZ, Sabbah BN, Lerman A, Zhu XY, Lerman LO. Arabi TZ, et al. Among authors: zhu xy. Cell Transplant. 2023 Jan-Dec;32:9636897221148771. doi: 10.1177/09636897221148771. Cell Transplant. 2023. PMID: 36644844 Free PMC article. Review.
Progressive Cellular Senescence Mediates Renal Dysfunction in Ischemic Nephropathy.
Kim SR, Puranik AS, Jiang K, Chen X, Zhu XY, Taylor I, Khodadadi-Jamayran A, Lerman A, Hickson LJ, Childs BG, Textor SC, Tchkonia T, Niewold TB, Kirkland JL, Lerman LO. Kim SR, et al. Among authors: zhu xy. J Am Soc Nephrol. 2021 Aug;32(8):1987-2004. doi: 10.1681/ASN.2020091373. Epub 2021 Jun 16. J Am Soc Nephrol. 2021. PMID: 34135081 Free PMC article.
Subtyping-based platform guides precision medicine for heavily pretreated metastatic triple-negative breast cancer: The FUTURE phase II umbrella clinical trial.
Liu Y, Zhu XZ, Xiao Y, Wu SY, Zuo WJ, Yu Q, Cao AY, Li JJ, Yu KD, Liu GY, Wu J, Sun T, Cui JW, Lv Z, Li HP, Zhu XY, Jiang YZ, Wang ZH, Shao ZM. Liu Y, et al. Among authors: zhu xy. Cell Res. 2023 May;33(5):389-402. doi: 10.1038/s41422-023-00795-2. Epub 2023 Mar 27. Cell Res. 2023. PMID: 36973538 Free PMC article. Clinical Trial.
Famitinib with Camrelizumab and Nab-Paclitaxel for Advanced Immunomodulatory Triple-Negative Breast Cancer (FUTURE-C-Plus): An Open-Label, Single-Arm, Phase II Trial.
Chen L, Jiang YZ, Wu SY, Wu J, Di GH, Liu GY, Yu KD, Fan L, Li JJ, Hou YF, Hu Z, Chen CM, Huang XY, Cao AY, Hu X, Zhao S, Ma XY, Xu Y, Sun XJ, Chai WJ, Guo X, Chen X, Xu Y, Zhu XY, Zou JJ, Yang WT, Wang ZH, Shao ZM. Chen L, et al. Among authors: zhu xy. Clin Cancer Res. 2022 Jul 1;28(13):2807-2817. doi: 10.1158/1078-0432.CCR-21-4313. Clin Cancer Res. 2022. PMID: 35247906 Free PMC article.
1,246 results